



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#B11A  
9/19/02

Applicant(s): *Turner et al.*

Group Art Unit: 1646

RECEIVED

SEP 18 2002

Application No.: 09/714,882

Examiner: O'Hara, E.B.

TECH CENTER 1600/2900

Filed: November 16, 2000

Attorney Docket No.: LEX-0091-USA

Title: Novel Human *Notch* Ligand Proteins  
and Polynucleotides Encoding the Same

**AMENDMENT; AND RESPONSE TO OFFICE ACTION DATED**  
**JUNE 13, 2002**

Commissioner for Patents  
Arlington, VA 22202

Sir:

The Applicants acknowledge the receipt of the Office Action ("the Action") mailed on June 13, 2002 (Paper No. 10), which has been carefully reviewed and studied. The Examiner is respectfully requested to enter the following amendments. Reexamination and reconsideration of the application is requested in view of the following amendments and remarks. In order to facilitate the Examiner's evaluation of the application, Applicants have attempted to address the rejections in Paper No. 10 in the same order in which they were originally raised.

Also included herewith are: as **Exhibit A**, a clean copy of the pending claims; as **Exhibit B**, a marked up copy of the original claims; as **Exhibit C**, the information provided regarding accession number Q9UGD3, which has been annotated as encoding a "Novel protein similar to SEL1L (Sel-1 suppressor of lin-12, *C. elegans*)-like"; as **Exhibit D**, an amino acid sequence comparison analysis between of SEQ ID NO:1 and Accession no. Q9UGD3.

The response is timely filed, and therefore Applicants believe no fees are due in connection with this response. However, the Commissioner is authorized to charge any necessary fees or credit any overpayment to Lexicon Genetics Incorporated Deposit Account No. 50-0892.